Development of commercialization platforms for single molecule imaging of GPCR oligomers via super-resolution microscopy
Lead Research Organisation:
Imperial College London
Department Name: Surgery and Cancer
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
People |
ORCID iD |
| Aylin Hanyaloglu (Principal Investigator) |
Publications
Fanelli F
(2020)
Integrated structural modeling and super-resolution imaging resolve GPCR oligomers.
in Progress in molecular biology and translational science
| Description | The goal of this 6 month Pathfinder Award was to carry out market research analysis and assess the intellectual property (IP) landscape for a novel technology to be potentially exploited as a drug discovery platform for a superfamily of receptors called G protein-coupled receptors (GPCRs). Market research identified need requirements, format of interaction and interest from industry, and the potential to protect the technology. Valuable feedback from industry strongly suggested further analysis/studies with additional GPCRs would facilitate uptake/financial investment. Through this process key contacts in pharmaceutical industry have been made and will be further developed. |
| Exploitation Route | The findings from this market research strongly suggest that further funding is to be sought to support basic research studies that assess the applicability of the screening technology to additional GPCRs. These receptors represent the most successful drug target and their number and play central role in health and disease. This would place this project funded by investment in this pathfinder award combined with the additional data would place us in a very strong position for Follow-on Funding schemes at BBSRC and run within Imperial College to develop commercialization of research at the early stages. |
| Sectors | Healthcare Pharmaceuticals and Medical Biotechnology |
| Description | Directing luteinising hormone receptor activity in vivo: A convergent approach to study GPCR molecular complexes |
| Amount | £1,065,319 (GBP) |
| Funding ID | BB/V006142/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2021 |
| End | 04/2024 |
| Description | PhD consumables grant |
| Amount | £8,440 (GBP) |
| Funding ID | Grant No. 01075/P67019 |
| Organisation | Genesis Research Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 03/2018 |
| Description | UKRI Impact Acceleration Funding-Pre-clinical models of a novel therapeutic agent in pre-term labour |
| Amount | £57,786 (GBP) |
| Funding ID | PSQ248_WRIB - MRC IAA |
| Organisation | Imperial College London |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2024 |
| End | 11/2024 |
| Description | Collaborations with AstraZeneca |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Our technology platform employed on this grant (single molecule, super-resolution imaging on the Nanoimager) will be applied in a new project with AstraZeneca on membrane tyrosine kinase receptors. |
| Collaborator Contribution | AstraZeneca have identified how cancer causing mutations in EGF receptor family members impact homo and heater dimerisation. They were seeking partners to be able to quantitate receptor complexes at the single molecule level, which our technology provides. |
| Impact | We jointly applied for a Crick-AstraZeneca alliance award and was successful in receiving 12 months of funding to commence in June 2024. |
| Start Year | 2023 |